← Back to headlines
Novartis Shares Rise After Multiple Sclerosis Pill Meets Clinical Trial Targets
Novartis stock gained momentum after announcing that its experimental oral medication successfully achieved primary endpoints in multiple sclerosis clinical trials.
1 Sept, 11:01 — 1 Sept, 11:01
Sources
Showing 1 of 1 sources
